We explored this hypothesis by evaluating the response of three lung adenocarcinoma cell lines that differ only in their EGFR genotype to the MET inhibitor SGX523 in vitro and in a murine xenograft model derived from the same cells. Here, MET is linked to lung adenocarcinoma.